SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer
GlobeNewswire · 5d ago
Edited Transcript of AXGN earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 5d ago
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 05/27 08:20
Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire · 05/20 12:00
84 Biggest Movers From Yesterday
Gainers Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares climbed 78.6% to close at $2.42 on Thursday after falling 10% on Wednesday.
Benzinga · 05/08 09:34
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/08 08:11
68 Stocks Moving In Thursday's Mid-Day Session
Gainers Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares jumped 114.4% to $2.9050 after falling 10% on Wednesday.
Benzinga · 05/07 16:42
WMC, TWLO, LCI and LYFT among midday movers
Seeking Alpha - Article · 05/07 16:40
AxoGen Inc (AXGN) Q1 2020 Earnings Call Transcript
Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President. Karen will begin our call with an overview of our Q1 performance, our response to the COVID-19 pandemic and provide an outlook on the developing recovery.
Motley Fool · 05/07 16:00
Benzinga's Top Upgrades, Downgrades For May 7, 2020
Benzinga · 05/07 13:54
Canaccord Genuity Downgrades Axogen to Hold, Announces $12 Price Target
Canaccord Genuity analyst Kyle Rose downgrades Axogen (NASDAQ:AXGN) from Buy to Hold and announces $12 price target.
Benzinga · 05/07 11:28
AxoGen EPS misses by $0.04, misses on revenue
AxoGen (NASDAQ:AXGN): Q1 Non-GAAP EPS of -$0.19 misses by $0.04; GAAP EPS of -$0.21 beats by $0.03. Revenue of $24.26M (+4.2% Y/Y) misses by $0.03M. Shares
seekingalpha · 05/07 01:29
Axogen Q1 EPS $(0.190) Misses $(0.150) Estimate, Sales $24.300M Miss $26.190M Estimate
Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.190) per share which missed the analyst consensus estimate of $(0.150) by 26.67 percent. This is a 26.67 percent decrease over losses of $(0.150) per share from the
Benzinga · 05/06 20:19
Axogen, Inc. Reports First Quarter 2020 Financial Results
ALACHUA, Fla., May 06, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today.
GlobeNewswire · 05/06 20:01
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 14:36
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc.
Benzinga · 05/03 12:46
Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline
Zacks · 04/29 17:34
Axogen Option Alert: Jun 19 $10 Calls Sweep (3) near the Ask: 1000 @ $0.604 vs 1 OI; Earnings 5/6 After Close Ref=$8.345
Benzinga · 04/24 18:54
Axogen sees Q1 revenue of ~$24M; class action lawsuit dismissed
seekingalpha · 04/23 17:13
Axogen Sees Prelim. Q1 Sales $24.3M vs $27.06M Est.
Benzinga · 04/23 11:03